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Abstract: Introduction: Metformin (MET), an old anti-diabetic drug, has proven 
unexpected anti-glioblastoma effects, by impacting cell proliferation, migration and 
invasion. However, its remarkable anti-cancer efficacy is mainly limited to the use of 
high millimolar concentrations in in vitro studies, which are hard to be attained in the 
clinical setting. Aim: The aim of this paper was to synthetize gold nanoparticles loaded 
with MET and to test if an enhanced drug delivery via nanotechnology could overcome 
the limitations of small drug concentrations. Materials and Methods: Gold nanoparticles 
were functionalized with chitosan (GNPc) and loaded with 80 μM of MET. Their size, 
zeta potential and stability were characterized and their internalization within tumor 
cells was assayed through dark field microscopy. Three primary glioblastoma stem cell 
lines were treated with 5, 10 and 20 μg/mL concentrations of nanoparticles and 
irradiated. The anti-tumoral effect was evaluated through the MTT cell viability assay. 
Results: MET-GNPc are easily synthetized and have a positive zeta potential, spherical 
shape and a median size of 26 nm. MET-GNPc have an increased cell internalization and 
affect the viability of all three glioblastoma cell lines used compared to control and free 
MET. However, their anti-cancer effect is not statistically different when compared to 
GNPc, although a slight tendency to a better response may be observed. 
Conclusion:Despite an increased cell internalization, the small micromolar 
concentrations of metformin does not bring an additional benefit to chitosan-based 
GNPs. Novel delivery methods being able to carry a higher drug concentration of 
metformin should be tested. 
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Introduction 
Metformin (MET), a well-known oral 
antidiabetic, has been regarded as an 
extremely promising anticancer agent in many 
cancer types. In vitro and in vivo experiments 
proved a myriad of mechanisms of action, 
including decreased cell proliferation, cell 
cycle arrest, autophagy, apoptosis and cell 
death in vitro with a concomitant activation of 
AMPK and inhibition of the mTOR pathway, 
while also sensitizing cells to radiotherapy (M. 
Aldea et al., 2014; M. D. Aldea et al., 2014; 
Carmignani et al., 2014; Nenu et al., 2014; 
Sesen et al., 2015; Soritau et al., 2011). Our 
team investigated MET in glioblastoma cell 
lines and proved a surprising reduction of 
glioblastoma stem-like cells proliferation (M. 
D. Aldea et al., 2014; Carmignani et al., 2014; 
Soritau et al., 2011). 
However, this benefits were observed 
mainly at supra-clinical doses of 1-10 mM, 
which are easily obtained in vitro or in vivo 
experiments, but are unlikely to be obtained in 
the clinical setting (M. Aldea et al., 2014). 
Clinical cancer trials that have tested MET 
with the same doses used in anti-diabetic 
therapy failed to translate into a relevant 
tumor response, possibly due to lack of MET 
adequate high concentrations for cancer cell 
killing (Kordes et al., 2015; Reni et al., 2016; 
Sayed, Saad, El Wakeel, Elkholy, & Badary, 
2015). 
We hypothesize that MET tumor targeted 
delivery by nanotechnology might overcome 
the ineffectiveness of small drug 
concentrations. Therefore, in this study, we 
synthetized gold nanoparticles loaded with 
micromolar concentrations of MET in order 
to test if such low dose compounds reach the 
anticancer effects observed with high free drug 
MET therapy. 
Materials and Methods 
Nanoparticles preparation and metformin 
loading 
Citrate-capped gold nanoparticles (GNPc) 
were synthetized following the 
Turkevich−Frens method and by slightly 
modifying the method used in our previous 
experiments (Aldea M, 2018; Potara, Maniu, & 
Astilean, 2009; Turkevich J, 1951). Briefly, 100 
mL of hydrogen tetrachloroaurate(III) 
trihydrate HAuCl4·3H2O (10-3 M) were 
heated to a boiling temperature and then 
mixed to trisodium citrate (10 mL, 38.8 × 10−3 
M) (Merck) under vigorous stirring. After the 
formation of a deep-red burgundy colloid, the 
stirring and boiling processed were continued 
for 10-15 min.  Subsequently, the heating was 
stopped and the stirring process was 
continued for another 15 min. Then, 3 ml of 
10-3 M HAuCl4 were mixed with 18 ml of 2 
mg/mL chitosan solution (medium molecular 
weight), and then heated to 50 ºC. The 
colloidal solutions were centrifugated and re-
suspended in ultrapure water. Loading of 
metformin hydrochloride (MET) (Sigma 
Aldrich) onto the surface of GNPc was 
performed by incubating the colloidal GNPc 
with MET at pH 3.5. The pH of the mixture 
was then adjusted to 8 with 1M NaOH. The 
obtained metformin gold nanoconjugates 
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(MET-GNPc) were subsequently washed to 
remove the free drug. All materials were 
purchased from Sigma Aldrich, unless 
otherwise specified.  
Structural characterization of NPs – zeta 
potential, gold concentration, size 
Optical extinction spectra of NPs were 
collected in a 2 mm quartz cell using a Jasco V-
670 spectrophotometer with 1 nm spectral 
resolution. The zeta potential was recorded at 
25 °C using a Malvern Zetasizer Nano ZS-90 
instrument. The concentration of gold in the 
colloidal suspension (μg/mL) was determined 
by atomic absorption spectroscopy (Avanta 
PM, GBC-Australia). Transmission Electron 
Microscopy (TEM) was used in our previous 
study to determine the median size of GNPc 
(Aldea M, 2018).  
Cell cultures 
Our in vitro experiment used three 
glioblastoma cell lines and a normal 
endothelial cell line. GM1 is a primary 
glioblastoma cell line isolated from freshly 
resected glioblastoma specimens that has been 
shown to express both stem cell markers and 
neural markers, as previously described by our 
team (12). After isolation and expansion in a 
serum-free medium enriched with growth 
factors, GM1 cells were subsequently cultured 
in Ham’s F-12 and DMEM media used in 1:1 
ratio, supplemented with 15% fetal calf serum 
(FCS), 100 U/ml penicillin and 100 μg/ ml 
streptomycin, 2mM L-glutamine, 1% non-
essential amino acids (NEA), 55 μM beta-
mercaptoethanol and 1 mM sodium pyruvate. 
Also, two commercial glioblastoma cell lines 
(A172 and U251, purchased from Sigma-
Aldrich) were cultured in DMEM medium 
supplemented with 2mM L-glutamine, 100 
U/ml penicillin and 100 μg/ ml streptomycin, 
1% NEA, 1 mM sodium pyruvate and 10% 
FCS.  
Human endothelial cells (HUVEC), 
purchased from the European Collection of 
Cell Cultures (ECACC, Porton Down, 
Salisbury, UK) served as “normal cell model” 
and were cultured in RPMI medium, 
supplemented with 10% fetal calf serum (FCS), 
gentamicin 50 μg/ml, and amphotericin 
100 μg/ml (Biochrom AG, Berlin, Germany). 
Cultures were maintained at 37 ºC in a 
humidified atmosphere of 95 % air and 5% 
CO2. All cell culture reagents were purchased 
from Sigma-Aldrich Corporation (St Louis, 
MO, USA), unless otherwise specified.  
NP administration and cell internalization 
For each of the cell lines used, uncapped 
GNP, GNPc and MET-GNPc were 
administered at dose concentrations of 5, 10 
and 20 μg/mL. Their internalization within 
cells was analyzed through dark field 
microscopy. Cells were cultured in Ibidi 30 μ-
Dish of 50 mm and treated for 24 h at a 
concentration of 10 μg/mL of each 
nanoparticle. An inverted Zeiss Axio Observer 
Z1 microscope with a halogen lamp (HAL100, 
100 W, Zeiss) focused on the sample at a 
constant intensity through a high numerical 
immersion dark field condenser (NA = 1.4) 
and the scattered light was collected by a LD 
Plan-Neofluar ×20 objective (NA = 0.4, Zeiss). 
Imaging acquisition was made with an 
AxioCam Icc digital camera and processed 
with the ZEN software. 
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Cell lines irradiation 
In order to test if MET-GNPc could be 
used as a radiosensitizer, cell lines were 
irradiated at megavoltage energies of 1.25 MV 
with 2, 4 and 6 Gy, by using a Cobalt 
Theratron100R. Control experiments were 
performed following exactly the same 
treatment protocol, but without irradiation. 
Cell viability after NP administration with 
or without irradiation 
After reaching a sub-confluence of 60-80%, 
cells were incubated with 5, 10 and 20 μg/mL 
of each nanoparticle and free drug. After 24 h, 
cell viability was assessed via the MTT 
proliferation test, which measured the 
mitochondrial activity of living cells. After 
removing the medium and washing three 
times with PBS, the yellow MTT solution [3-
(4,5-dimethylthiazolyl- 2)-2,5-
diphenyltetrazolium bromide] was added and 
the plate was left at 37 ºC for 1 h to allow MTT 
to be metabolized. The resulting purple 
formazan was then re-suspended in 150 μl 
DMSO and placed on a shaking table. The 
reduction of MTT to formazan takes place 
only when mitochondrial enzymes are active; 
therefore, the conversion rate can directly 
estimate the number of living cells. The 
concentration was determined by optical 
density at 492 nm by using a fluorescence 
microplate reader (Synergy 2, BioTek, 
Winooski, VT, USA).  
Statistical analysis 
All experiments were repeated three times 
and expressed as mean ± SEM of three 
independent biological replicates. The 
comparison between groups was assessed by 
the one-way ANOVA followed by Bonfferoni’s 
multiple comparison post-test. The statistical 
significance was set at p < 0.05 (GraphPad 
version 5.0 San Diego CA, USA).  
Results 
Physico-chemical characteristics of MET-
GNPc and GNPc  
The formation of the MET-GNPc 
nanoparticle was validated through 
spectroscopic measurements. By analysing the 
extinction spectra of MET-GNPc and GNPc, it 
may be observed that the coloidal solution 
maintaines its stability in the presence of MET 
as the form of the spectra does not change.  
The optical spectra of colloidal solutions in 
Figure 1 exhibit a dominant extinction band 
located at 525 nm for GNPc, which shows the 
dipolar plasmon resonance of spherical NPs. 
For the MET-GNPc the plasmonic band has 
smaller wavelengths compared with GNPc. 
This difference is caused by the change of the 
refraction index of nanoparticles as a result of 
MET disposal near the gold surface after its 
incorporation within the polymeric matrix. 
In the extinction spectrum of the MET-
GNPc, a supplementary extinction band may 
be observed in the ultraviolet field at 230 nm, 
characteristic to MET, which proves the 
successful loading of GNPc with MET. MET 
loading efficiency and its quantity were 
assessed through UV-vis measurements of the 
initial MET used for incubation, of the 
supernatant collected after conjugation, of the 
mixture of MET-GNPc before and after 
centrifugation. As a supplementary control 
measurement, the concentration of loaded 
MET was measured by inducing an acid 
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medium (pH 2.5), which immediately led to 
the release of the entire MET quantity from the 
GNPc, followed by a 20 min centrifugation at 
12.000 rotations per minute. MET 
concentration was determined by 
measurements of atomic absorption. In 
optimal incubation conditions, we observed 
that MET loads on GNPc at a concentration of 
80 μM.  
Also, the complex stability was monitored 
in time through UV-vis-NIR spectroscopy. It 
has been observed that in normal 4 degrees 
refrigerator conditions, the colloidal MET-
GNPc maintains its stability for a minimum of 
2 months. 
In our previous work, we have already 
demonstrated a positive zeta potential and a 
medium size of nearly 26 nm of GNPc (Aldea 
M, 2018). The positive zeta potential appears 
as a result of the protonated amino groups 
from the chitosan chain which characterizes 
both GNPc and MET-GNPc.  
 
 
Figure 1 - UV-vis-NIR extinction spectra of GNPc 
(a) and MET-GNPc (b) 
 
Cellular uptake of GNPs analyzed by dark 
field imaging 
GNPs are easily visualized through dark 
field microscopy because of their surface 
plasmon resonances which make them able to 
strongly scatter the visible light. Cells were 
incubated at the same concentration of GNPc 
and MET-GNPc for 24h. The orange-red spots 
correspond to the light-scattering 
nanoparticles. As observed in Figure 2, both 
GNPc and MET-GNPc are highly internalized 
within the analyzed cell lines and they are 
located mostly throughout all the cytoplasm. 
 
 
Figure 2 - Dark field microscopy images of GM1 cells 
incubated with GNPc and MET-GNPc for 24 h. (A), 
(a) GNPc; (B), (b) MET-GNPc 
 
GNPc and MET-GNPc impacts the viability 
of glioblastoma cell lines 
The tested cell lines included both 
glioblastoma stem-like cells (GM1) and 
commercial non-stem glioblastoma cells 
(A172 and U251) in order to investigate if the 
stem cell character confers any resistance or 
sensitivity to MET-GNPc. Also, an endothelial 
cell lines was used as a normal cell line.  
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The MTT viability test showed that the 
most sensitive cell lines were GM1 and U251, 
which were impacted by the 10 and 20 μg/mL 
concentrations of both GNPc and MET-GNPc 
(p<0.001) (Figure 3). Although MET-GNPc 
significantly affects cell proliferation when 
compared to control and uncapped GNPc, 
there is no difference when compared to the 
chitosan-capped GNPc (p>0.05). Therefore, it 
seems that the tumor cell viability is affected 
mainly by the chitosan component of the 
nanoparticles and that the benefit of MET 
loading is only minor and does not lead to an 
additional benefit in terms of cell viability.  
MET-GNPc and GNPc slightly affect the 
endothelial cell line, especially when used at 
the 20 μg/mL concentration (p<0.05).
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Figure 3 - MTT viability assay after 24h incubation with treatments (control, GNP, GNPc, MET-GNPc, MET). 
Increasing doses of each treatment (5 μg/mL, 10 μg/mL and 20 μg/mL) showed that cell viability was affected in a 
dose dependent manner (non-significant for the 5 μg/mL dose). Cell viability is mostly affected by the GNPc and 
MET-GNPc used at the 20 μg/mL concentration for each glioblastoma cell line (p<0.001). HUVEC cells were also 
affected by NP treatments, but only when treated with the 20 μg/mL concentration (p<0.05) 
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Figure 4 - Irradiated versus non-irradiated cells. Glioblastoma cell lines are affected by irradiation with a slight 
tendency of an enhanced response when combined to GNPc and MET-GNPc treatment (p<0.05). The addition of 
nanoparticles does not increase the toxicity of irradiation upon HUVEC, which are resistant to radiotherapy 
(p>0.05) 
 
Radiotherapy shows no additional benefit 
when combined with GNPc or MET-GNPc  
 
We investigated if such GNPc with or 
without MET could sensitize cells to 
irradiation. All tested NPs were used at a 10 
μg/mL concentration and irradiated with 
increasing doses of 2, 4 and 6 Gy. HUVEC 
normal cell lines proved the highest resistance 
to irradiation and the combination between 
irradiation and nanoparticles did not impact 
their viability (p>0.05).  
The response of the tumoral cell lines was 
different mainly depending on their 
proliferation index, but also on their intrinsic 
radioresistance. The A172 cell line was 
impacted by the 2 Gy and 4 Gy irradiation 
fractions, with a slight benefit when GNPc was 
combined with 4 Gy irradiation, but 
intriguingly, the 6 Gy dose was no different 
than the unirradiated control. The U251 cell 
line, which has a lower proliferation index, 
proved to be resistant at small doses of 
irradiation, but the combination of 4 Gy 
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irradiation and GNPc with/without MET was 
more toxic and decreased cell viability 
compared to each treatment alone (p<0.05). 
However, this additional benefit was not 
observed when the 6 Gy dose was used, despite 
the fact that this dose impacted cell 
proliferation.  
The stem-like cell GM1 proved the best 
response when radiotherapy at higher doses 
was combined with nanoparticles as shown by 
their decreased viability when 4 and 6 Gy doses 
of irradiation were combined with MET-
GNPc or GNPc (Figure 4). 
Discussions  
MET has shown an excellent anti-
glioblastoma activity in numerous in vitro 
studies, by inhibiting the self-renewal capacity 
of glioblastoma stem cells, expression of stem 
cell markers, as well as their invasion and 
migration properties. However, the 
antiproliferative effects of MET were proven 
mainly when used at high drug 
concentrations, as many in vitro experiments 
used millimolar metformin concentrations  
(Song et al., 2018). From a translational point 
of view, such concentrations are not attained 
in the clinics by the maximal anti-diabetic dose 
normally used. Therefore, in this study, our 
aim was to test if an enhanced delivery and 
internalization of MET via nanoparticles, 
could overcome the limitation of small drug 
concentrations.  
Nanotechnology holds an excellent 
potential of providing a preferential drug 
administration within the tumor, with an 
enhanced internalization and efficient drug 
delivery at the targeted site (Suri, Fenniri, & 
Singh, 2007).  Our team previously synthetized 
chitosan-capped GNP and proved that such 
nanoparticles are highly internalized by 
glioblastoma-stem like cells and by normal 
osteoblasts cells. Intriguingly, GNPc proved a 
selective anti-proliferative effect for 
glioblastoma cells, as compared with un-
capped GNP which had no anti-tumor effect. 
Despite an important intracellular 
accumulation within osteoblasts, GNPc 
showed no toxicity on the normal cell line. The 
increased intratumoral internalization of 
GNPc and their selective cytotoxicity on 
cancer cells have suggested that such NPs 
could be a promising vector for anti-cancer 
drugs (Aldea M, 2018).  
Therefore, our team further synthetized 
GNPc and managed to functionalize them 
with small micromolar concentration of MET, 
in order to test if their enhanced delivery 
would lead to a therapeutic drug efficiency 
within the tumor cells.  The synthesis of MET 
nanoparticles was an easy, reproducible 
method and resulted in the development of a 
stable compound, with physico-chemical 
characteristics similar to GNPc. However, 
although both GNPc and MET-GNPc had an 
important intracellular accumulation and 
proved to impact the survival of glioblastoma 
cells, there were no statistically significant 
differences between GNPc and MET-GNPc, 
suggesting that MET does not bring an 
additional benefit when used in small 
micromolar drug concentrations.  
Considering the important anti-cancer 
effects proved by MET used in millimolar 
concentrations, further research must be made 
in order to find a suitable delivery method. 
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Kumar et al. synthetized a similar gold 
nanoparticle for the targeted delivery of 
metformin by capping GNPs with hyaluronic 
acid. The enhanced MET delivery was able to 
improve the anti-cancer activity of the MET-
GNP complex compared to free MET in the 
treatment of liver cancer cells (Kumar, Raja, 
Sundar, Gover Antoniraj, & Ruckmani, 2015). 
An alternative way would be the development 
of NPs that would permit higher MET 
binding, by paying attention also to the fact 
that the increasing concentration of NPs 
would increase the quantity of excipients 
within the brain. Possible biodegradable NPs 
are more desirable for this purpose. Also, 
another strategy to increase drug 
concentrations would be the intratumoral 
administration of MET or within the tumoral 
cavity after surgical resection (Aldea et al., 
2016).  
Conclusion 
Herein, we have developed a novel GNP 
loaded with MET, by using a biocompatible 
and biodegradable polymer, chitosan, as a 
reducing agent. This formulation exhibited 
high cell internalization due to the use of 
GNPc and had an increased anti-glioblastoma 
activity compared to free MET used in small 
micromolar concentrations. However, MET-
GNPc does not add a significant benefit when 
compared to GNPc possible due to the small 
MET concentrations used for binding. 
Therefore, an increased internalization of 
MET-GNPc loaded with micromolar 
concentrations of MET does not prove the 
same anti-cancer effectiveness of millimolar 
concentrations of free MET. Improved 
delivery methods with an increased MET 
loading should be tested.  
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